pyrazines has been researched along with Carcinoma, Non-Small Cell Lung in 111 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.90) | 18.2507 |
| 2000's | 43 (38.74) | 29.6817 |
| 2010's | 48 (43.24) | 24.3611 |
| 2020's | 19 (17.12) | 2.80 |
| Authors | Studies |
|---|---|
| Bironzo, P; Bungaro, M; Capelletto, E; Denis, L; Koustenis, A; Novello, S | 1 |
| Castellano, GM; Garbuzenko, OB; Malhotra, J; Minko, T; Pine, SR; Sabaawy, HE; Zeeshan, S | 1 |
| Meiners, S; Meul, T; Schlesser, C; Stathopoulos, G | 1 |
| Chen, DS; Fang, Y; Gao, W; Gu, Y; Huang, R; Ma, P; Shu, Y; Wu, X; Zhang, HW | 1 |
| Downward, J; Hancock, DC; Herbert, E; Horswell, S; Janes, MR; Li, LS; Molina-Arcas, M; Moore, C; Mugarza, E; Rana, S; Romero-Clavijo, P; van Maldegem, F | 1 |
| Anderton, MJ; Bethel, P; Breed, J; Cook, C; Davies, EJ; Dobson, A; Dong, Z; Fairley, G; Farrington, P; Feron, L; Flemington, V; Gibbons, FD; Graham, MA; Greenwood, R; Hanson, L; Hopcroft, P; Howells, R; Hudson, J; James, M; Jones, CD; Jones, CR; Lamont, S; Lewis, R; Li, Y; Lindsay, N; McCabe, J; McGuire, T; Rawlins, P; Roberts, K; Sandin, L; Simpson, I; Swallow, S; Tang, J; Tomkinson, G; Tonge, M; Wang, Z; Ward, RA; Zhai, B | 1 |
| Burns, TF; Camidge, DR; Cetnar, J; Gerber, DE; Horobin, JC; Jeong, W; Keegan, M; Kelly, RJ; Li, M; Morgensztern, D; Ramalingam, SS; Scaglioni, PP; Spigel, DR; Vaikus, L; Weaver, DT; Zhang, S | 1 |
| Früh, M; Peters, S; Schmid, S | 1 |
| Ahn, MJ; Cantarini, M; Cho, BC; Frewer, P; Han, JY; Kim, SW; Kowalski, D; Lee, JS; Mellemgaard, A; Orlov, S; Ottesen, L; Ou, X; Oxnard, G; Sequist, LV; Su, WC; Verheijen, RB; Yang, JC; Yu, H | 1 |
| Ahn, MJ; Frigault, MM; Ghiorghiu, D; Goto, K; Horn, L; Kim, SW; Mann, H; Ohe, Y; Oxnard, GR; Ramalingam, SS; Saka, H; Thress, KS; Vishwanathan, K; Yang, JC; Yu, H | 1 |
| Arai, S; Atagi, S; Fukuda, K; Han, X; Hanayama, R; Ishimura, A; Kaira, K; Kita, K; Matsumoto, I; Matsumoto, K; Nishiyama, A; Ohtsubo, K; Suzuki, T; Takayama, K; Takeuchi, S; Taniguchi, H; Taniguchi, Y; Tanimoto, A; Terashima, M; Uehara, H; Wang, R; Wang, W; Yamada, T; Yamano, T; Yamashita, K; Yano, S; Yoshimura, A | 1 |
| Ahmed, GF; Chang, JH; Chen, GY; Egile, C; Fang, J; Frigault, MM; Hartmaier, R; He, JX; Huang, JA; Li, W; Liu, XQ; Mellemgaard, A; Morgan, S; Shu, YQ; Verheijen, RB; Wu, YL; Yang, JJ; Yang, L; Yang, N; Zhou, C | 1 |
| Cai, T; Du, W; Fu, Y; Huang, JA; Lei, Z; Liu, T; Liu, Z; Wang, A; Zeng, Y; Zhang, Y; Zhu, J | 1 |
| Branigan, TB; D'Andrea, AD; DeCaprio, JA; Deraska, P; Kozono, D; Reavis, HD; Rivas, HG; Sambel, L; Schade, AE; Shapiro, GI | 1 |
| Ali, A; Bassal, MA; Bassères, DS; Bizzarri, R; Branstrom, A; Bueno, R; Castaño, J; Ciampi, R; Clohessy, JG; Crucitta, S; Csizmadia, E; Danesi, R; De Rienzo, A; Del Re, M; Fhu, CW; Fox, S; Giorgetti, A; Gustafson, CE; Klein, AM; Kocher, O; Krishnan, I; Levantini, E; Levy, RD; Li, J; Magli, MC; Maroni, G; Maymi, VA; Meyerovitz, CV; Pandell, N; Panella, R; Savova, V; Storti, B; Tenen, DG; Tramontozzi, PJ; Vermilya, K; Weetall, M; Welner, RS; Yang, H; Zhang, J; Zilionis, R | 1 |
| Ahmed, GF; Hayama, M; Hida, T; Hirashima, T; Kurata, T; Mellemgaard, A; Ohe, Y; Ou, X; Oxnard, GR; Saka, H; Sugibayashi, K; Verheijen, RB; Yoh, K | 1 |
| Cao, L; Chen, G; Chen, Y; Cheng, Y; Fan, Y; Fang, J; Guo, Q; Han, Z; Jiang, L; Li, J; Li, X; Liang, Z; Lu, S; Luo, X; Ma, R; Ren, Y; Shi, J; Su, W; Sun, S; Wang, L; Xu, H; Yang, N; Zhang, H; Zhou, J | 1 |
| Abel, L; Baschnagel, AM; Clark, PA; Elnaggar, JH; Kaushik, S; Kimple, RJ; Kromke, AC; Leal, TA; Longhurst, CA; Nickel, KP; Skiba, JH; VanBeek, HJ; Zhao, SG | 1 |
| Dawar, R; Drusbosky, LM; Ikpeazu, CV; Rodriguez, E | 1 |
| Markham, A | 1 |
| Bai, R; Chen, N; Fan, Y; Hao, LJ; Hao, Y; Li, GS; Liu, YJ; Mao, Y; Shi, C; Wang, YJ; Xia, GX; Yu, JX; Zhang, CC; Zhang, J; Zhang, LD; Zhao, F | 1 |
| Ahmed, S; Blackhall, F; Chen, J; Ciuleanu, TE; Kim, JH; Mezger, J; Park, K; Poondru, S; Thomas, M; VanTornout, JM; Whitcomb, D | 1 |
| Baek, B; Hyun, SY; Kim, B; Kim, Y; Lee, HJ; Lee, HY; Lee, J; Min, HY; Pham, PC | 1 |
| Asahina, S; Azuma, K; Fukuoka, M; Hayashi, H; Hida, T; Ikeda, S; Inoue, A; Iwamoto, Y; Kiura, K; Komatsu, K; Morita, S; Nakagawa, K; Nakagawa, T; Nishio, M; Satouchi, M; Sugawara, S; Takeda, K | 1 |
| Alcoser, SY; Aziz, A; Borgel, S; Bottaro, DP; Colantonio, S; Dieckman, L; Doroshow, JH; Hiltke, T; Hollingshead, MG; Kaczmarczyk, J; Kinders, RJ; Lee, YH; Navas, T; Parchment, RE; Pfister, TD; Saul, RG; Takebe, N; Tomaszewski, JE; Whiteley, G | 1 |
| Akazawa, R; Azuma, K; Fukuoka, M; Hayashi, H; Inoue, A; Kaneko, Y; Kang, JH; Kim, SW; Kiura, K; Morita, S; Murakami, H; Nakagawa, K; Nakagawa, T; Nishio, M; Nokihara, H; Park, K; Seto, T; Shimazaki, M; Takeda, K; Tsai, CM; Yang, JC | 1 |
| Dhillon, S | 1 |
| Horn, L; Jie, F; Kelly, RJ; Krivoshik, A; Shepherd, FA | 1 |
| Hirano, M; Kaneko, N; Konagai, S; Koshio, H; Kuromitsu, S; Matsuya, T; Mori, M; Sakagami, H; Takeuchi, M; Tanaka, H; Yamamoto, H; Yamanaka, Y; Yuri, M | 1 |
| Ahuja, HG; Blank, JH; Campbell, TC; Hernan, HR; Hoang, T; Huie, MS; Johnson, PH; Kim, K; Kirschling, RJ; Kolesar, JM; Larson, MM; Oettel, KR; Robinson, EG; Traynor, AM; Wims, ME; Zhang, C | 1 |
| Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J | 1 |
| Chen, CC; Cron, KR; D'Andrea, AD; Hsieh, G; Kozono, D; Kushwaha, DS; Merzon, D; Rameseder, J; Zhu, K | 1 |
| Baska, F; Breza, N; Kékesi, L; Kéri, G; Németh, G; Őrfi, L; Pató, J; Sipos, A | 1 |
| An, M; Hu, J; Hu, R; Li, X; Ruan, K; Shen, J; Song, G; Wu, N | 1 |
| Karthik, S; Ravikumar, V; Sankar, R; Varunkumar, K | 1 |
| Ji, Z; Jiang, X; Lei, Y; Li, H; Sun, M; Wu, G | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kathawala, RJ; Patel, A; Robey, RW; Shukla, S; Talele, TT; Wang, YJ; Zhang, H; Zhang, YK | 1 |
| Cui, YJ; Fei, HR; Li, ZM; Sun, BL; Sun, YK; Wang, FZ; Wang, XY; Yang, XY; Zhang, JG | 1 |
| Drucker, L; Gottfried, M; Zismanov, V | 1 |
| Adjei, AA; Aubry, MC; Bearden, JD; Foster, NR; Johnson, DB; Mandrekar, SJ; Mattar, BI; Meyers, JP; Molina, JR; Northfelt, DW; Rowland, KM; Schild, SE; Thomas, SP; Zhao, Y | 1 |
| Ando, M; Bouchier-Hayes, L; Brenner, MK; Dotti, G; Hoyos, V; Ramos, CA; Tao, W; Yagyu, S | 1 |
| Anusha, C; Karthik, S; Ravikumar, V; Sankar, R; Varunkumar, K | 1 |
| Cho, J; Jang, HJ; Lee, HJ; Lee, HY; Lee, JJ; Lee, JS; Liu, D; Min, HY; Oh, SH; Park, SH; Wistuba, II; Yun, HJ | 1 |
| James, M; Jeong, JH; Lee, Y; Wang, Y; You, M | 1 |
| Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Henley, AT; Hunter, JE; Lainchbury, M; Matthews, TP; McHardy, T; Osborne, J; Perkins, ND; Raynaud, FI; Reader, JC; Swales, K; Tall, M; Valenti, MR; Walton, MI | 1 |
| Eckhardt, SG; Gadgeel, SM; Gedrich, R; Gogov, S; Juergens, RA; Macaulay, VM; McCarthy, S; Middleton, MR; Poondru, S; Rudin, CM; Stephens, AW | 1 |
| Bach, S; Bazin, MA; Evenou, P; Marchand, P; Marhadour, S; Piessard, S; Roussakis, C; Rousseau, B; Ruchaud, S; Tomasoni, C; Vaisberg, AJ | 1 |
| Boyd, TE; Hynes, SM; Kang, JH; Kim, SW; Lin, AB; Lin, J; Myrand, SP; Novello, S; Park, K; Pinder-Schenck, M; Richards, DA; Rosenberg, R; Scagliotti, G; Smith, D; Smyth, EN; Su, WC; Wijayawardana, S | 1 |
| Liang, Y; Lin, Y; Liu, Y; Yin, W; Zhang, J | 1 |
| Adam, A; Barry, ER; Beran, G; Castriotta, L; Clark, E; D'Cruz, CM; Henry, RE; Ladd, B; Markovets, A; Qing, W; Reimer, C; Ren, Y; Schuller, AG; Su, W; Zhou, F; Zinda, M | 1 |
| Ahn, MJ; Arpornwirat, W; Bazhenova, L; Chen, J; Chiappori, AA; Chow, LQ; de Lima, LG; Dechaphunkul, A; Eaton, K; Gadgeel, SM; Juergens, RA; Leighl, NB; Medley, S; Poondru, S; Rizvi, NA; Rudin, CM; Singh, M; Steinberg, J; Sunpaweravong, P | 1 |
| Albain, KS; Chansky, K; Crowley, J; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Vogel, SJ | 1 |
| Carrell, JA; Humphreys, R; Luster, TA; McCormick, K; Sun, D | 1 |
| Ceresa, C; Giaccone, G; Giovannetti, E; Honeywell, R; Laan, AC; Peters, GJ; Voortman, J | 1 |
| Camacho, FJ; Elrafei, T; Gucalp, R; Ho, L; Li, T; Perez-Soler, R; Piperdi, B; Rigas, JR | 1 |
| Adachii, M; Ando, K; Hirose, T; Hosaka, T; Inoue, F; Ishida, H; Kadofuku, T; Kanome, T; Kusumoto, S; Ohmori, T; Ohnishi, T; Okuda, K; Saijo, N; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Bedor, M; Burrows, W; Edelman, MJ; Krasna, MJ; Smith, R; Suntharalingam, M | 1 |
| Albanell, J; Belda-Iniesta, C; Cejas, P; Chattopadhyay, S; Cortes-Sempere, M; de Castro-Carpeño, J; Gonzalez-Barón, M; Machado-Pinilla, R; Manguan-García, C; Moratilla, C; Nistal, M; Perona, R; Rodriguez-Fanjul, V; Rovira, A; Sánchez-Pérez, I; Tapia, M | 1 |
| Bodkin, D; Chiappori, A; Eton, O; Favis, R; Fenton, D; Halmos, B; Hirsh, V; Liu, H; Lynch, TJ; Middleman, EL; Shepherd, FA; Trepicchio, WL | 1 |
| Biesma, B; Bosquée, L; Chan, KC; De Marinis, F; Gans, S; Germonpré, P; Gervais, R; Lee, JS; Makhson, A; Manikhas, G; Morgan, B; Park, K; Planchard, D; Ramlau, R; Reck, M; Scagliotti, GV; Szczesna, A; Vansteenkiste, J; von Pawel, J; Zhu, Y | 1 |
| Gu, L; Kirshner, J; Lerro, K; Lilenbaum, R; Vokes, E; Wang, X | 1 |
| Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T | 1 |
| Cho, SH; Jones, DR; Lee, JK; Liu, Y; Nagji, AS | 1 |
| Argiris, A; Belani, CP; Gandara, DR; Gitlitz, B; Koczywas, M; Lara, PN; Lau, DH; Leighl, N; Longmate, J; Mack, PC; Ramalingam, S; Reckamp, K; Shepherd, FA; Wright, JJ | 1 |
| Bae, MS; Dong, MS; Gong, YD; Kang, NS; Kim, N; Lee, SB | 1 |
| Assaraf, YG; Chan, ET; Cloos, J; de Wilt, LH; Jansen, G; Kirk, CJ; Kruyt, FA; Peters, GJ; Schimmer, AD; van Meerloo, J | 1 |
| Besse, B; Ducourtieux, M; Khayat, D; Lafontaine, C; Lumbroso, J; Mathiot, C; Pignon, JP; Planchard, D; Soria, JC; Taillade, L; Veillard, AS | 1 |
| Hasegawa, S; Hashimoto, M; Lee-Kawabata, M; Masuyama, T; Naito, Y; Ogawa, H; Tamaki, H | 1 |
| Bathini, V; Bradley, K; Hanrahan-Boshes, M; Hutchinson, L; Perez-Soler, R; Piperdi, B; Walsh, WV; Zhou, Z | 1 |
| Dennis, PA; Gills, JJ; Hollander, MC; Kawabata, S; Lopiccolo, J; Mercado-Matos, JR; Wilson, W | 1 |
| Bruyère, C; Eamvijarn, A; Herz, W; Kijjoa, A; Kiss, R; Lefranc, F; Manoch, L; Mathieu, V; Silva, A | 1 |
| Bao, Y; Burks, SG; Gillenwater, HH; Jones, DR; Kozower, BD; Moskaluk, CA; Olazagasti, J; Petroni, GR; Philips, J; Rehm, PK | 1 |
| Adams, J; Elliott, PJ; Holland, JF; Jiang, JD; Liebes, L; Ling, YH; Muggia, FM; Perez-Soler, R | 1 |
| Liebes, L; Ling, YH; Perez-Soler, R; Zou, Y | 1 |
| Ikezoe, T; Kobayashi, M; Koeffler, HP; Saito, T; Taguchi, H; Yang, Y | 1 |
| Broad, RM; Denlinger, CE; Jones, DR; Keller, MD; Mayo, MW | 1 |
| Bold, RJ; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
| Bunn, PA | 1 |
| Denlinger, CE; Jones, DR; Keller, MD; Rundall, BK | 1 |
| Denlinger, CE; Jones, DR; Rundall, BK | 1 |
| Reddy, KG | 1 |
| Belani, CP | 1 |
| Schenkein, DP | 2 |
| Dubey, S; Schiller, JH | 1 |
| Edelman, MJ | 2 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Alexandre, J | 1 |
| Bold, RJ; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Mack, PC | 1 |
| Scagliotti, G | 1 |
| Bonomi, P; Villaflor, V | 1 |
| Lilenbaum, R; Raez, LE | 1 |
| Giaccone, G; Voortman, J | 1 |
| Soria, JC | 1 |
| Auberger, J; Hilbe, W; Loeffler-Ragg, J; Wurzer, W | 1 |
| Akerley, W; Axelrod, R; Belt, R; Carbone, DP; Crawford, J; Fanucchi, MP; Fidias, P; Fossella, FV; Govindan, R; Kashala, O; Kelly, K; Limentani, SA; Natale, R; Raez, LE; Reimers, HJ; Ribeiro, M; Robert, F; Schiller, JH; Sheng, S | 1 |
| Fenk, R; Garcia-Pardillos, G; Haas, R; Kronenwett, R; Meier, A; Neukirchen, J; Rohr, UP; Rohrbeck, A; Steidl, U | 1 |
| Checinska, A; Giaccone, G; Kruyt, FA; Rodriguez, JA; Voortman, J | 1 |
| Jung, CS; Khuri, FR; Sun, SY; Zhou, Z | 1 |
| Davies, AM; Doroshow, JH; Gandara, DR; Gumerlock, PH; Kashala, O; Koczywas, M; Lara, PN; Lau, DH; Lenz, HJ; Longmate, J; Quinn, DI; Schenkein, D | 1 |
| Chen, S; Hu, L; Khuri, FR; Liu, X; Lonial, S; Sun, SY; Yue, P | 1 |
| Giaccone, G; Honeywell, R; Kuenen, BC; Peters, GJ; Smit, EF; van de Velde, H; Voortman, J | 1 |
| Abou El Hassan, MA; Giaccone, G; Kruyt, FA; Resende, TP; Voortman, J | 1 |
| Ling, YH; Perez-Soler, R; Piperdi, B | 1 |
| Checińska, A; Giaccone, G; Voortman, J | 1 |
| Beckett, LA; Christensen, S; Davies, AM; Gandara, DR; Ho, C; Lara, PN; Lau, DH; Metzger, AS; Tanaka, M | 1 |
| Bold, R; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Ruel, C; Schenkein, DP; Shibata, S | 1 |
| Honma, Y; Kanatani, Y; Yamamoto-Yamaguchi, Y | 1 |
15 review(s) available for pyrazines and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Single agent VS-6766 or VS-6766 plus defactinib in
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins p21(ras); Pyrazines; Sulfonamides | 2022 |
Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Imidazoles; Lung Neoplasms; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyridazines; Pyrimidines; Triazines | 2021 |
Savolitinib: First Approval.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; China; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Approval; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Pyrazines; Stomach Neoplasms; Triazines | 2021 |
Gilteritinib: First Global Approval.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Lung Neoplasms; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic | 2019 |
The potential role of proteasome inhibitors in the treatment of lung cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines | 2004 |
Use of proteasome inhibition in the treatment of lung cancer.
Topics: Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2004 |
Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Glutamates; Guanine; Humans; Lung Neoplasms; Medical Oncology; Pemetrexed; Pyrazines | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Preclinical data with bortezomib in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Interactions; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2005 |
Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines | 2005 |
The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Radiation-Sensitizing Agents | 2005 |
Proteasome inhibitors in lung cancer.
Topics: Animals; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2006 |
Other compounds and targets in non-small cell lung cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Ligands; Lung Neoplasms; Membrane Glycoproteins; Proteasome Inhibitors; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
New developments in chemotherapy for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epothilones; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Pyrazines | 2006 |
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2006 |
32 trial(s) available for pyrazines and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Focal Adhesion Protein-Tyrosine Kinases; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Proto-Oncogene Proteins p21(ras); Pyrazines; Salvage Therapy; Sulfonamides; Survival Rate | 2020 |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Salvage Therapy; Survival Rate; Triazines | 2020 |
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Topics: Acrylamides; Aniline Compounds; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazines; Triazines | 2020 |
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Triazines | 2021 |
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C.
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Pyrazines; Triazines | 2021 |
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Topics: Carcinoma; Carcinoma, Non-Small-Cell Lung; Exons; Humans; Lung Neoplasms; Pyrazines; Triazines | 2021 |
Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Placebos; Platinum Compounds; Pyrazines; Receptors, Somatomedin | 2017 |
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines | 2018 |
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines | 2018 |
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Survival Rate | 2019 |
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Pyrazines; Treatment Outcome; Vorinostat | 2014 |
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome | 2013 |
A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pyrazines; Survival Analysis | 2015 |
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Somatomedin; Young Adult | 2016 |
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Checkpoint Kinase 1; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate | 2017 |
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate; Treatment Outcome | 2009 |
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Pyrazines | 2009 |
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Early Termination of Clinical Trials; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protease Inhibitors; Pyrazines; Treatment Failure; Tumor Burden; Venous Thrombosis | 2010 |
Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Early Termination of Clinical Trials; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Protease Inhibitors; Pyrazines; Radiotherapy; Respiratory Insufficiency | 2010 |
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Therapy, Combination; Dyspnea; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Pyrazines; Survival Analysis; Thrombocytopenia | 2010 |
Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Docetaxel; Female; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Taxoids | 2009 |
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pyrazines; Taxoids | 2011 |
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Pyrazines; Survival Rate | 2012 |
Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Pyrazines; Survival Rate; Treatment Outcome; United States; Vascular Endothelial Growth Factor A | 2012 |
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; Gene Expression Profiling; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Vorinostat | 2012 |
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Taxoids; Treatment Outcome; United States | 2006 |
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome | 2006 |
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines | 2007 |
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pemetrexed; Pyrazines; Survival Analysis | 2007 |
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Neutropenia; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome | 2008 |
64 other study(ies) available for pyrazines and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
Topics: Animals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; DNA; Humans; Lung; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; TOR Serine-Threonine Kinases; Triazoles | 2022 |
Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Lymphoma, Mantle-Cell; Metformin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2022 |
Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Triazines | 2022 |
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Survival; Imidazoles; Lung Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Pyrazines; Pyridones; Pyrimidinones; Receptor, IGF Type 1; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Discovery; Drug Therapy, Combination; Female; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Structure; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
Topics: Acrylamides; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazines; Triazines | 2020 |
Non-Small Cell Lung Cancer Responds to Osimertinib plus Savolitinib.
Topics: Acrylamides; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazines; Triazines | 2020 |
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Topics: Acrylamides; Aged, 80 and over; Aniline Compounds; Animals; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 3-alpha; Humans; Imidazoles; Lung Neoplasms; Male; Mice; Models, Biological; Mutation; Phosphorylation; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; RNA, Messenger; Up-Regulation | 2020 |
Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Focal Adhesion Kinase 1; Gefitinib; Humans; Integrin alphaVbeta3; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Osteopontin; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Sulfonamides | 2020 |
MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity.
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Cycle Proteins; Checkpoint Kinase 1; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mitosis; Multiprotein Complexes; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Signal Transduction; Trans-Activators | 2021 |
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Epithelial Cells; Humans; Lung Neoplasms; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Polycomb Repressive Complex 1; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; RNA-Seq; Single-Cell Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Female; Heterografts; Humans; Isoxazoles; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Pyrazines; Treatment Outcome | 2021 |
Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Gastric Mucosa; Haplorhini; Humans; Lung; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Quinolines; Rats; Rats, Sprague-Dawley; Stomach; Stomach Neoplasms | 2017 |
Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dasatinib; Humans; Imidazoles; Immunohistochemistry; MCF-7 Cells; Pyrazines; Pyrimidines; Receptor, IGF Type 1; Receptors, Somatomedin; src-Family Kinases; Xenograft Model Antitumor Assays | 2018 |
Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Topics: AC133 Antigen; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Gene Knock-In Techniques; Hepatocyte Growth Factor; Humans; Indicators and Reagents; Lung Neoplasms; Mice, Transgenic; Neoplastic Stem Cells; Phenotype; Pyrazines; Sulfonamides; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Topics: Animals; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mutation; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Pyrrolidines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer.
Topics: Animals; Boronic Acids; Bortezomib; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; DNA Repair; Fanconi Anemia Complementation Group D2 Protein; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Rad51 Recombinase; Radiation-Sensitizing Agents; Radiation, Ionizing; Radiotherapy; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays | 2013 |
Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction | 2013 |
The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Microscopy, Electron, Scanning; Nanospheres; Pyrazines; Silicon Dioxide; Spectrophotometry, Ultraviolet | 2014 |
Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Depsipeptides; Drug Synergism; Histone Deacetylases; Histones; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrazines; Up-Regulation | 2014 |
Inhibition of autophagy by autophagic inhibitors enhances apoptosis induced by bortezomib in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Epithelial Cells; Humans; Pyrazines | 2014 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Interactions; Drug Resistance, Multiple; HEK293 Cells; Humans; Imidazoles; Lung Neoplasms; Mitoxantrone; Models, Molecular; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Pyrazines | 2014 |
The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Topics: Antineoplastic Agents; Antirheumatic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Chloroquine; DNA Damage; DNA Repair; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; MAP Kinase Kinase 4; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Serine | 2014 |
Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Unfolded Protein Response | 2014 |
Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cloning, Molecular; Dimerization; Enzyme Activation; Gene Knockdown Techniques; Genes, Transgenic, Suicide; Genetic Vectors; Green Fluorescent Proteins; Humans; Immunoblotting; Luciferases, Firefly; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, SCID; Organic Chemicals; Pyrazines; X-Linked Inhibitor of Apoptosis Protein | 2014 |
Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Depsipeptides; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; NF-kappa B; Pyrazines; Reactive Oxygen Species; Transcription, Genetic | 2015 |
Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Imidazoles; Lung Neoplasms; Mice; Models, Biological; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Protein Stability; Pyrazines; Receptor, IGF Type 1; Signal Transduction; src-Family Kinases | 2015 |
Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lung Neoplasms; Mice; Mutation; Pyrazines; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Topics: 4-Aminopyridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclin-Dependent Kinases; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; HT29 Cells; Humans; Irinotecan; Lung Neoplasms; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyrazines; Xenograft Model Antitumor Assays | 2016 |
Discovery of Novel (Imidazo[1,2-a]pyrazin-6-yl)ureas as Antiproliferative Agents Targeting P53 in Non-small Cell Lung Cancer Cell Lines.
Topics: Animals; Antineoplastic Agents; BALB 3T3 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Lung Neoplasms; Mice; Pyrazines; Tumor Suppressor Protein p53; Urea | 2016 |
IRE1α-TRAF2-ASK1 pathway is involved in CSTMP-induced apoptosis and ER stress in human non-small cell lung cancer A549 cells.
Topics: A549 Cells; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Survival; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Endoribonucleases; Humans; Lung Neoplasms; MAP Kinase Kinase Kinase 5; Mitochondria; Protein Binding; Protein Serine-Threonine Kinases; Pyrazines; RNA, Small Interfering; Signal Transduction; TNF Receptor-Associated Factor 2 | 2016 |
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-myc; Pyrazines; TOR Serine-Threonine Kinases; Triazines | 2016 |
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
Topics: Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Death; Cell Line, Tumor; Death Domain Receptor Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Lung Neoplasms; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2009 |
Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Pyrazines; Quinazolines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2009 |
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chromones; Cisplatin; Dual Specificity Phosphatase 1; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Morpholines; NF-kappa B; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; RNA Interference; Signal Transduction; Sulfones | 2009 |
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.
Topics: Algorithms; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Gene Expression Profiling; Humans; Hydroxamic Acids; Lung Neoplasms; Multigene Family; Pyrazines; Vorinostat | 2010 |
A novel 3-arylethynyl-substituted pyrido[2,3,-b]pyrazine derivatives and pharmacophore model as Wnt2/β-catenin pathway inhibitors in non-small-cell lung cancer cell lines.
Topics: Antineoplastic Agents; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Models, Molecular; Molecular Structure; Pyrazines; Pyridines; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured; Wnt Proteins | 2011 |
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
Topics: Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Proteasome Endopeptidase Complex; Protein Binding; Pyrazines | 2012 |
Curative resection of double primary lung cancer after 15-month bortezomib administration.
Topics: Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Pneumonectomy; Pyrazines; Treatment Outcome | 2012 |
Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
Topics: Activating Transcription Factor 3; Animals; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Mice; Mice, Nude; Multiple Myeloma; Nelfinavir; Protease Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous | 2012 |
Secondary metabolites from a culture of the fungus Neosartorya pseudofischeri and their in vitro cytostatic activity in human cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cytostatic Agents; Dioxoles; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; MCF-7 Cells; Microscopy, Phase-Contrast; Mitosis; Neosartorya; Pyrazines; Pyridines; Sesquiterpenes; Soil Microbiology | 2012 |
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Topics: Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Dose-Response Relationship, Drug; G2 Phase; Humans; Immunohistochemistry; Lung Neoplasms; Microtubules; Mitosis; Multienzyme Complexes; Mutation; Precipitin Tests; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2003 |
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Antineoplastic Agents; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Survival; Cysteine Endopeptidases; Cytochrome c Group; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Immunoblotting; Indicators and Reagents; Lung Neoplasms; Membrane Potentials; Mitochondria; Models, Chemical; Multienzyme Complexes; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Reactive Oxygen Species; Time Factors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme-Linked Immunosorbent Assay; Genes, jun; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Transcription Factor AP-1; Tumor Suppressor Protein p53 | 2004 |
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Butyrates; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Cysteine Endopeptidases; Histone Deacetylases; Humans; Interleukin-8; Lung Neoplasms; Multienzyme Complexes; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transcription, Genetic; Transcriptional Activation; Treatment Outcome; Tumor Cells, Cultured | 2004 |
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2004 |
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Proteins; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factor RelA; Transcription, Genetic; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2004 |
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Mitochondria; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Transcription, Genetic; Vorinostat | 2004 |
Activity of bortezomib in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
Emerging advances in the management of lung cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Paclitaxel; Polyglutamic Acid; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
Lung cancer - Second Annual Winter Conference.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines | 2005 |
[Proteasome inhibitors].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Drug Therapy, Combination; Female; Graft vs Host Reaction; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Comorbidity; Deoxycytidine; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Risk Factors; Ventricular Dysfunction, Left | 2006 |
[Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic; Research; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A | 2006 |
The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Genes, p53; Genetic Therapy; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Transfection; Tumor Cells, Cultured | 2007 |
Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Caspases; Cisplatin; Cytochromes c; Humans; Lung Neoplasms; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Cells, Cultured; Up-Regulation | 2007 |
Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Survivin; Taxoids; Tumor Cells, Cultured | 2007 |
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; Survivin; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2007 |
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; NF-kappa B; Proteasome Inhibitors; Pyrazines; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Drug Interactions; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Tumor Cells, Cultured | 2007 |
The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; Cell Line, Tumor; Humans; Lung Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Sensitivity and Specificity | 2007 |
Vesnarinone and glucocorticoids cooperatively induce G1 arrest and have an anti-tumour effect on human non-small cell lung carcinoma cells grown in nude mice.
Topics: Alkaline Phosphatase; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Division; Dexamethasone; Drug Synergism; G1 Phase; Glucocorticoids; Humans; Lung Neoplasms; Mice; Neoplasm Transplantation; Pyrazines; Quinolines; Retinoblastoma Protein; Tumor Cells, Cultured | 1999 |